dapivirine Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Dapivirine is a non-nucleoside reverse transcriptase inhibitor developed at Janssen Therapeutics. The International Partnership for Microbicides has held exclusive worldwide rights to dapivirine since 2014, building upon a 2004 royalty-free license to develop dapivirine-based microbicides for women in resource-poor countries.   Wikipedia

Chemistry

  • SMILES: Cc1cc(C)c(Nc2ccnc(Nc3ccc(C#N)cc3)n2)c(C)c1
  • InChIKey: ILAYIAGXTHKHNT-UHFFFAOYSA-N
  • Mol. Mass: 329.41
  • ALogP: 4.76
  • ChEMBL Molecule:
    dapivirine  
More Chemistry

Pharmacology

Alternative names

aids-105293 | dapivirine | r-147681 | tmc120 | tmc-120 | tmc120-r147681

Organizations (17)

Research & Development (17)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (12)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (12)


 

Acquired Immunodeficiency Syndrome (Phase 1/Phase 2)

Contraception (Phase 1)

Contraception Behavior (Phase 1)

Healthy Volunteers (Phase 1/Phase 2)

Hemorrhage (Phase 1/Phase 2)

HIV (Phase 2)

HIV-1 (Phase 1/Phase 2)

HIV Infections (Phase 3)

Penile Diseases (Phase 1)

Pharmacokinetics (Phase 1/Phase 2)

Pharmacology (Phase 1)

Women (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 44
  • # of Trial Organizations: 17

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue